GuercioliniR. Mode of action of Orlistat. Int J Obes Relat Metab Disord21(Suppl 3):S12–S23, 1997.
2.
KridelSJ, AxelrodF, RozenkrantzN, SmithJW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res64: 2070–2075, 2004.
SmithS. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J8: 1248–1259, 1994.
5.
KuhajdaFP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition16: 202–208, 2000.
6.
MenendezJA, VellonL, MehmiI, OzaBP, RoperoS, ColomerR, LupuR. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A101: 10715–10720, 2004.
7.
MarmorMD, SkariaKB, YardenY. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys58: 903–913, 2004.
8.
RossJS, McKennaBJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest19: 554–568, 2001.
9.
XingX, WangSC, XiaW, ZouY, ShaoR, KwongKY, YuZ, ZhangS, MillerS, HuangL, HungMC. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med6: 189–195, 2000.
10.
HulitJ, LeeRJ, RussellRG, PestellRG. ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochem Pharmacol64: 827–836, 2002.
11.
ChettyR. P27 protein and cancers of the gastrointestinal tract and liver: an overview. J Clin Gastroenterol37: 23–27, 2003.
12.
NahtaR, TakahashiT, UenoNT, HungMC, EstevaFJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res64: 3981–3986, 2004.
13.
MenendezJA, MehmiI, VermaVA, TengPK, LupuR. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog41: 164–178, 2004.
14.
TorgersonJS, HauptmanJ, BoldrinMN, SjostromL. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of Orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care27: 155–161, 2004.
